Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:1790
Name malignant mesothelioma
Definition A cell type cancer that has_material_basis_in mesothelial tissue that develops from the thin layer of tissue that covers many of the internal organs.
Source DiseaseOntology.org
Alt Ids DOID:6965 DOID:4487 DOID:7434
Path disease disease of cellular proliferation cancer cell type cancer malignant mesothelioma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
CD274 positive Pembrolizumab malignant mesothelioma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01592383 Phase II Erlotinib Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT02071862 Phase I Everolimus + Telaglenastat Erlotinib + Telaglenastat Docetaxel + Telaglenastat Telaglenastat Paclitaxel + Telaglenastat Cabozantinib + Telaglenastat Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Completed USA 0
NCT02293005 Phase II Alisertib Alisertib in Malignant Mesothelioma Completed USA 0
NCT02341625 Phase Ib/II BMS-986148 BMS-986148 + Nivolumab A Study of BMS-986148 in Patients With Select Advanced Solid Tumors Terminated USA | ITA | CAN | BEL 3
NCT02349958 Phase II Mitomycin C Cisplatin Doxorubicin Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy Unknown status USA 0
NCT02357147 Phase II Cisplatin + Pemetrexed Disodium Amatuximab Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM). (ARTEMIS) Terminated USA | ITA | FRA | DEU 2
NCT02372227 Phase I Defactinib + VS-5584 A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma Terminated USA 1
NCT02611024 Phase Ib/II Irinotecan + Lurbinectedin Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors Recruiting USA | ESP 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | ITA | FRA | ESP | DEU | CAN 13
NCT02628535 Phase I Obrindatamab Safety Study of MGD009 in B7-H3-expressing Tumors Terminated USA | CAN 1
NCT02760797 Phase I Emactuzumab + Selicrelumab A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed USA | FRA | BEL 0
NCT02856425 Phase I Nintedanib + Pembrolizumab Trial Of Pembrolizumab And Nintedanib (PEMBIB) Recruiting FRA 0
NCT02860286 Phase II Tazemetostat Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma Completed USA | FRA 1
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02977156 Phase I Ipilimumab + JX-594 Immunization Strategy With Intra-tumoral Injections of Pexa-Vec With Ipilimumab in Metastatic / Advanced Solid Tumors. (ISI-JX) Completed FRA 0
NCT03007030 Phase II Brentuximab vedotin Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery Recruiting USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03319537 Phase Ib/II MLN4924 Cisplatin + MLN4924 + Pemetrexed Disodium Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma Active, not recruiting USA 0
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Terminated USA 0
NCT03502746 Phase II Nivolumab + Ramucirumab Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma Active, not recruiting USA 0
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03531840 Phase II Olaparib Olaparib in People With Malignant Mesothelioma Completed USA 0
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Completed USA 0
NCT03546426 Phase I Aldesleukin + Pembrolizumab Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX) Recruiting ITA 0
NCT03556228 Phase I VMD-928 Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma Recruiting USA 0
NCT03590054 Phase I Abexinostat + Pembrolizumab Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA 0
NCT03654833 Phase II Bemcentinib + Pembrolizumab Rucaparib Abemaciclib Atezolizumab + Bevacizumab Dostarlimab-gxly + Niraparib Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma (MiST) Recruiting 1
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Terminated USA 0
NCT03872206 Phase Ib/II HPN536 Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression Active, not recruiting USA 0
NCT03936959 Phase I LY3434172 A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer Completed USA | FRA | BEL 2
NCT04173338 Phase I Cabozantinib + Pemetrexed Disodium Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma Terminated USA 0
NCT04328844 Phase I IOA-244 A Study to Assess a PI3Kdelta Inhibitor (IOA-244) in Patients With Metastatic Cancers Recruiting ITA 1
NCT04462809 Phase II Talazoparib Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOthelioma (TALAMESO) Not yet recruiting 0
NCT04515836 Phase II Olaparib Olaparib in Patients With HRD Malignant Mesothelioma Recruiting USA 0
NCT04606381 Phase I Amivantamab-vmjw + Lazertinib Amivantamab-vmjw + Lazertinib + rHuPH20 Amivantamab-vmjw Amivantamab-vmjw + rHuPH20 A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies Recruiting USA | CAN 2
NCT04857372 Phase I IAG933 A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors Recruiting USA | ITA | FRA | ESP | DEU | CAN 4
NCT05006794 Phase I GS-9716 + Sacituzumab govitecan-hziy GS-9716 Docetaxel + GS-9716 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies Recruiting USA 0
NCT05047536 Phase I KZR-261 KZR-261 in Subjects With Advanced Solid Malignancies Recruiting USA 0
NCT05070247 Phase I TAK-500 Pembrolizumab + TAK-500 A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors Recruiting USA 0
NCT05071014 Phase I Pembrolizumab A Study of Pembrolizumab and Cryoablation in People With Mesothelioma Recruiting USA 0
NCT05098405 Phase I MP0317 First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid Tumors Recruiting FRA 1
NCT05238883 Phase I HFB200301 HFB200301 + Tislelizumab A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors Recruiting USA | ESP 0
NCT05275478 Phase Ib/II TNG908 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Recruiting USA | FRA 0
NCT05278975 Phase Ib/II Thiostrepton Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma Recruiting 1
NCT05298592 Phase I BMS-986406 + Nivolumab BMS-986406 A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors Recruiting USA | ESP | BEL 0
NCT05415098 Phase I APG-5918 Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas Recruiting USA 0
NCT05455424 Phase II Niraparib Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO) Recruiting 1
NCT05579366 Phase Ib/II PRO1184 PRO1184 for Advanced Solid Tumors (PRO1184-001) Recruiting USA 0